# Sciety

> Sciety is a VC fund in Stockholm backing Health Care and Biotechnology. See 46 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Stockholm, Sweden
- Total investments: 46
- Last investment: Mar 2026
- Lead investor: 93%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sciety/
- Website: https://www.sciety.com/
- Facebook: https://www.facebook.com/scietyinfo/

Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations,helping to bring breakthroughs in healthcare to people all over the world.Investment areas: biotechnology, pharmaceuticals, medical technology and health tech.Deal size: 1 – 15 MEUR.Sciety AB is regulated by Finansinspektionen (the Swedish financial supervisory authority) and is a member of the Swedish Private Equity & Venture Capital Association (SVCA) and SwedenBIO (trade association for the Swedish life science industry).

## Contacts

5 contacts available for Sciety. Shizune tracks 10 team members at Sciety. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sciety?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $128k–$2.3M |
| Series A | $439k–$6.5M |
| Venture - Series Unknown | $1.6M–$6.9M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 17 | 37% |
| Biotechnology | 13 | 28% |
| Medical | 10 | 22% |
| Pharmaceutical | 10 | 22% |
| Health Diagnostics | 6 | 13% |

31 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 14 | 30% |
| Series A | 10 | 22% |
| Venture - Series Unknown | 7 | 15% |
| Funding Round | 4 | 9% |
| Series B | 1 | 2% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 28 | 61% |
| Ukraine | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Charlotte Smirnova Lindblom | Corporate Communications Manager | 0 | https://shizune.co/investors/profile/charlotte-smirnova-lindblom |
| Erik Hjelmstedt | Chairman | 0 | https://shizune.co/investors/profile/erik-hjelmstedt |
| Andreas Lindblom | Founding Partner and CEO | 13 | https://shizune.co/investors/profile/andreas-lindblom |
| Bengt Julander | Senior Advisor | 0 | https://shizune.co/investors/profile/bengt-julander-2556 |
| Christina Sterner | Back Office Manager | 0 | https://shizune.co/investors/profile/christina-sterner |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Everdrone | Everdrone is at the forefront of a new era in public safety, where emergency drones are a critical and integrated part of everyday life. Our drones provide critical support to emergency response organisations by reaching incident scenes faster than any ground unit to gather vital information and deliver life-saving medical equipment. | $3.9M | Venture - Series Unknown | Mar 19, 2026 |  |
| NEOGAP Therapeutics | NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects. | $9.8M | Venture - Series Unknown | Feb 11, 2026 |  |
| Hälsa Hemma | Hälsa Hemma provides app-based healthcare and home visits for consultations, examinations, and sample collection. | $4.2M |  | Sep 03, 2025 |  |
| TIRmed Pharma | TIRmed Pharma develops drug candidates addressing major clinical needs. | $4.7M | Venture - Series Unknown | Apr 09, 2025 |  |
| PeptiSystems | PeptiSystems focuses on manufacturing and supplying instruments for the solid-phase synthesis of peptide and oligonucleotide therapeutics. | $4.1M | Venture - Series Unknown | Dec 20, 2024 |  |
| Capitainer | Capitainer enables patients to collect their own volume-defined dried blood spot at home.Capitainer started in 2016. Their technology is a volumetric blood collection device that enables patients to conveniently and safely collect blood samples in the comfort of their own home, our technology is more accurate than today’s solutions. Capitaineroffers impressive cost and environmental savings for healthcare providers managing millions of conventional blood samples annually. | $1.4M | Series A | Feb 15, 2024 |  |
| NEOGAP Therapeutics | NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects. | $4.9M | Venture - Series Unknown | Nov 09, 2023 |  |
| PharmNovo | PharmNovo's goal is to develop novel Delta Opioid Receptor Agonists that are safe and effective for chronic pain treatment (DORAs). This is a very different target than traditional opioid drugs, which have caused an epidemic of addiction and toxicity.The company addresses the significant unmet medical need for safe and effective chronic paintreatments, which affects up to 30% of the adult population in the United States and Europe. | $2.2M |  | Sep 26, 2023 |  |
| NEOGAP Therapeutics | NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects. | $5.1M | Venture - Series Unknown | Jun 22, 2023 |  |
| Encare | Encare was established in 2009 to implement the ERAS Protocols on a global basis by- providing training to health care professionals on the ERAS Protocols- providing an interactive and web-based information system for evidence based - best practice management (EBM)The company has developed an interactive, user-friendly interface forthe collection, documentation and follow-up on critical performance and quality parameters as lined out by leading clinical experts in respective protocol[1] based on, at any time, best practice and evidence.The data collected in the web-based solution is interactive and offers immediate feedback of performance, which will generate significant and sustainable improvement of efficiency and quality of care as well as generate substantial health care savings.Encare has the rights to commercialize surgical protocols developed by the ERAS Society. The company has so far rolled out the audit system to more than 120 hospitals in Canada, France, Norway, Poland, Sweden, South Africa, Switzerland, the United Kingdom, Argentina, Mexico, Colombia, Brazil, Singapore and the United States.The ERAS Society was formed in 2001 with the aim to establish evidence based protocols as best practice standards in perioperative care. ERAS Society has published a wide range of publications regarding protocols and guidelines for enhanced recovery after surgery. | $1.6M | Venture - Series Unknown | May 29, 2023 |  |

10 of 46 investments shown.

## Co-investors
- [Sciety Venture Partners](https://shizune.co/investors/profile/sciety-venture-partners) — VC Fund, 4 deals together
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund, 2 deals together
- [Industrifonden](https://shizune.co/investors/profile/industrifonden) — VC Fund, 2 deals together
- [Karolinska](https://shizune.co/investors/profile/karolinska) — VC Fund, 2 deals together
- [3T Invest](https://shizune.co/investors/profile/3t-invest) — VC Fund, 1 deal together
- [Chalmers Ventures AB](https://shizune.co/investors/profile/chalmers-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Chalmers Ventures AB](https://shizune.co/investors/profile/chalmers-ventures) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund

## Featured in investor lists
- [All Investors in Sweden](https://shizune.co/investors/investors-sweden)
- [All VC Funds in Sweden](https://shizune.co/investors/vc-funds-sweden)
- [Health Care Investors in Europe](https://shizune.co/investors/health-care-investors-europe)
- [Health Care VC Funds in Europe](https://shizune.co/investors/health-care-vc-funds-europe)
- [Health Care VC Funds in Sweden](https://shizune.co/investors/health-care-vc-funds-sweden)
- [Biotechnology VC Funds in Europe](https://shizune.co/investors/biotechnology-vc-funds-europe)

## FAQ

### What does Sciety invest in?

Sciety invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 46 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sciety's check size?

Sciety typically joins rounds of $128k–$2.3M at Seed, $439k–$6.5M at Series A and $1.6M–$6.9M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sciety participates in.

### How do I contact Sciety?

Public channels for Sciety include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sciety?

The team at Sciety includes Charlotte Smirnova Lindblom (Corporate Communications Manager), Erik Hjelmstedt (Chairman) and Andreas Lindblom (Founding Partner and CEO), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co